Casimersen
Amondys (casimersen) is an oligonucleotide pharmaceutical. Casimersen was first approved as Amondys on 2021-02-25. It is used to treat duchenne muscular dystrophy in the USA. Amondys 45's patents are valid until 2030-11-12 (FDA).
| Trade Name | Amondys |
|---|---|
| Common Name | Casimersen |
| Indication | duchenne muscular dystrophy |
| Drug Class | Antisense oligonucleotides |
